Taken together, PD-L2 is a prognostic biomarker for LGGs patients that may provide novel insights into glioma individualized therapeutic strategies and guide effective immunotherapy and chemotherapy. The gene discussed is PDCD1LG2; the disease is central nervous system cancer.